(NASDAQ: KPTI) Karyopharm Therapeutics's forecast annual revenue growth rate of 29.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 24.03%.
Karyopharm Therapeutics's revenue in 2026 is $146,067,000.On average, 9 Wall Street analysts forecast KPTI's revenue for 2026 to be $2,701,883,047, with the lowest KPTI revenue forecast at $2,362,152,759, and the highest KPTI revenue forecast at $3,124,711,509. On average, 7 Wall Street analysts forecast KPTI's revenue for 2027 to be $3,951,474,147, with the lowest KPTI revenue forecast at $2,646,300,824, and the highest KPTI revenue forecast at $6,685,642,577.
In 2028, KPTI is forecast to generate $5,941,060,916 in revenue, with the lowest revenue forecast at $2,667,763,266 and the highest revenue forecast at $10,317,748,241.